Article Text

Download PDFPDF
Original article
Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up
  1. Alfredo Pece1,
  2. Vincenzo Isola1,
  3. Stefano Piermarocchi2,
  4. Giliola Calori3
  1. 1Department of Ophthalmology, Melegnano Hospital, Milan, Italy
  2. 2Department of Ophthalmology, University of Padua, Padua, Italy
  3. 3Statistics and Epidemiology Unit, San Raffaele University Hospital, Milan, Italy
  1. Correspondence to Dr Alfredo Pece, Department of Ophthalmology, Melegnano Hospital, Via Pandina 1, 20077 Vizzolo Predabissi, Milan, Italy; pece.retina{at}


Purpose To evaluate the efficacy and safety of intravitreal ranibizumab (Lucentis) in patients with treatment-naive retinal vein occlusion.

Design Prospective, consecutive, non-comparative, interventional case series.

Participants Seventeen eyes of 17 consecutive patients with naive retinal vein occlusion.

Methods Consecutive patients were recruited and received, on demand, intravitreal 0.5 mg of ranibizumab; nine had central retinal vein occlusion (CRVO) and eight had branch retinal vein occlusion (BRVO). Pre- and postoperative clinical evaluation included measurement of best corrected visual acuity (BCVA) for distance, and near vision (MNREAD time, reading fluency), contrast sensitivity, colour fundus photography, fluorescein angiography and optical coherence tomography (OCT). All subjects were followed for a minimum of 12 months.

Main outcome measures Change in BCVA, contrast sensitivity, angiographic leakage, OCT central macular thickness (CMT), number of treatments.

Results Patients with CRVO had mean pre-treatment BCVA of 20/240 (1.08±0.25 logarithm of the minimum angle of resolution (logMAR)) and final BCVA of 20/46 (0.36±0.16 logMAR), with significant improvement at 1 year of follow-up (p<0.0001). At 12 months mean BCVA improved to 36.7 letters, with a gain of 6.4 lines, and OCT showed that the mean CMT was 271 μm, with a mean reduction of 360 μm (p<0.0001) from baseline (mean 631 μm). Patients with BRVO had mean pre-treatment BCVA of 20/126 (0.80±0.29 logMAR) and final BCVA of 20/50 (0.41±0.23 logMAR) (p<0.0001). The mean OCT CMT was 278 μm, with a mean reduction of 275 μm (p<0.0001) from baseline (mean 553 μm). Contrast sensitivity, MNREAD time and reading fluency improved significantly in the treated eyes. No ocular or systemic side effects were observed. Eyes with CRVO received an average of 3.0 injections (range 2–4) and those with BRVO 3.6 (range 3–4).

Conclusions Intravitreal ranibizumab for the management of naive CRVO or BRVO can favourably modify the course of the occlusion, indicating that short- and long-term blockade of vascular endothelial growth factor (VEGF)-A may restore the integrity of the inner blood–retinal barrier, reduce CMT and significantly improve visual function, with a good safety profile. Further prospective long-term studies are warranted to confirm the efficacy, safety and optimal treatment regimen for intravitreal ranibizumab.

  • Retina
  • treatment other

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Presented as a paper at the Annual AAO/SOI Joint Meeting, Atlanta, USA, 8–11 November 2008.

  • Funding Supported by Fondazione Retina 3000 Milan.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh